Presented by Swiss Re
Thought provoking insights on the evolving insurance claims landscape. Swiss Re's first issue of their bi-annual magazine sharing trends that are shaping the claims environment and perspectives in both global outlooks and local realities.
Presented by McKinsey & Company
Updating technology is essential but perceived as costly and difficult. Here’s our guide for property and casualty carriers.
Presented by bolttech
Global insurtech bolttech, in partnership with GSMA’s Mobile World Live, has released a new whitepaper that explores how mobile network operators (MNOs) can tap into the fast-growing embedded insurance market, projected to surge from US$156B in 2024 to US$703B by 2029.
IIS Executive Insights Cyber Expert: David Piesse, CRO, Cymar
Click here to read David Piesse's bio
Presented by RGA
Behavioral science techniques can significantly improve customer understanding of life insurance products and help reverse declining ownership rates, with RGA research offering practical strategies insurers can implement today.
Presented by Milliman
Predictive models in insurance are often built on data influenced by human decisions, structural inequities, and representation bias. Simply removing sensitive attributes does not eliminate bias. Milliman’s paper outlines the legal and business imperatives for fairness in actuarial practices and introduces core concepts of group fairness. It also presents practical bias-mitigation methodologies aimed at reducing legal exposure while maintaining predictive performance.
Presented by McKinsey
Presented by Milliman
Milliman analyzed the adoption and use of generative artificial intelligence (AI) by insurers in the European market. Generative AI refers to deep-learning models capable of creating content by learning from the data they are trained on. This white paper focuses on large language models and vision algorithms and covers their applications in insurance, organizational approaches to implementing and scaling gen AI, the role of internal expertise, and technical and compliance challenges.
Presented by RGA
Glucagon-like peptide 1 receptor agonists (GLP-1s) may be poised to become an integral part of treating a range of chronic diseases – from cardiovascular disease to cancer – and could improve all-cause mortality rates.
